SCHEMBL22970168

SCHEMBL22970168

CSCC[C@H](NC(=O)c1cccc(CN)c1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.49
HDAC2 Q92769 5/20 0.49
HDAC3 O15379 4/20 0.49
HDAC4 P56524 4/20 0.49
HDAC7 Q8WUI4 4/20 0.49
HDAC10 Q969S8 4/20 0.49
HDAC11 Q96DB2 4/20 0.49
HDAC8 Q9BY41 4/20 0.49
HDAC6 Q9UBN7 4/20 0.49
HDAC9 Q9UKV0 4/20 0.49
HDAC5 Q9UQL6 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
FNTA P49354 5/20 0.48
FNTB P49356 5/20 0.48
PGGT1B P53609 2/20 0.48
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241960 1.00 HDAC1 (0.49) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21241791 0.92 HDAC1 (0.48) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21242074 0.92 PHGDH (0.51) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL22971500 0.92 PHGDH (0.51) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21241796 0.92 SCD (0.50) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21224249 0.92 SCD (0.50) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL28518773 0.90 FNTA (0.53) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21224212 0.89 MEN1 (0.50) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21224214 0.89 MEN1 (0.50) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL21224324 0.89 SCD (0.57) MEN1KMT2AALDH1A1MAPTSCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC1 242/4885HDAC2 323/4885HDAC3 231/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB HDAC1 242/4885HDAC2 323/4885HDAC3 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.